Beijing, Feb 3 : China’s CanSino Biologics Inc.has got green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.
The independent committee “found the drugmaker’s Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data,” the report said.
No adverse events related to the vaccine had occurred, according to the Xinhua news agency.
The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc.and the Academy of Military Sciences in China.
CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China’s Ministry of Science and Technology, said in September last year
.
